Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Increase in the dosage amount of vitamin D3 preparations by switching from calcium carbonate to lanthanum carbonate.

Hyodo T, Kawakami J, Mikami N, Wakai H, Ishii D, Yoshida K, Iwamura M, Hida M, Kurata Y.

Ther Apher Dial. 2014 Jun;18 Suppl 1:14-7. doi: 10.1111/1744-9987.12198.

PMID:
24953761
2.

Improvement of MBD parameters in dialysis patients by a switch to, and combined use of lanthanum carbonate: Josai Dialysis Forum collaborative study.

Shinoda T, Yamasaki M, Chida Y, Takagi M, Tanaka Y, Ando R, Suzuki T, Tagawa H.

Ther Apher Dial. 2013 Apr;17 Suppl 1:29-34. doi: 10.1111/1744-9987.12041.

PMID:
23586510
3.

Efficacy of continuous oral administration of lanthanum carbonate over 24 months.

Ishizu T, Hong Z, Matsunaga T, Kaneko Y, Taru Y.

Ther Apher Dial. 2013 Apr;17 Suppl 1:22-8. doi: 10.1111/1744-9987.12042.

PMID:
23586509
4.

Effects of switching from calcium carbonate to lanthanum carbonate on bone mineral metabolism in hemodialysis patients.

Manabe R, Fukami K, Ando R, Sakai K, Kusumoto T, Hazama T, Adachi T, Kaida Y, Nakayama Y, Ueda S, Kohno K, Wada Y, Yamagishi S, Okuda S.

Ther Apher Dial. 2013 Apr;17 Suppl 1:35-40. doi: 10.1111/1744-9987.12037. Erratum in: Ther Apher Dial. 2013 Aug;17(4):466.

PMID:
23586511
5.

Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study.

Toida T, Fukudome K, Fujimoto S, Yamada K, Sato Y, Chiyotanda S, Kitamura K.

Clin Nephrol. 2012 Sep;78(3):216-23.

PMID:
22874110
6.

Clinical effects of long-term (36-month) lanthanum carbonate administration in hemodialysis patients in Japan.

Kishi Y, Obara Y, Hara K, Yamashiro H, Kurosawa N, Takada D.

Ther Apher Dial. 2014 Jun;18 Suppl 1:9-13. doi: 10.1111/1744-9987.12197.

PMID:
24953760
7.

[Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].

Lorenzo Sellares V, Torregrosa V.

Nefrologia. 2008;28 Suppl 3:67-78. Spanish.

8.

Three-year follow-up of lanthanum carbonate therapy in hemodialysis patients.

Takeuchi K, Matsuda E, Sekino M, Hasegawa Y, Kamo Y, Kikuchi N, Sekino H.

Ther Apher Dial. 2013 Apr;17 Suppl 1:15-21. doi: 10.1111/1744-9987.12045.

PMID:
23586508
9.

Multicenter study on the long-term (3-year) efficacy of lanthanum carbonate in dialysis patients.

Ando R, Yama S, Ohnishi T, Iwamoto S, Kimura H, Chida Y, Ishida Y, Yamada K, Inagaki Y, Takayama M, Tachibana K, Kikuchi K, Inoue A, Ohtsuka M.

Ther Apher Dial. 2014 Jun;18 Suppl 1:2-8. doi: 10.1111/1744-9987.12206.

PMID:
24953759
10.

Lanthanum carbonate delays progression of coronary artery calcification compared with calcium-based phosphate binders in patients on hemodialysis: a pilot study.

Ohtake T, Kobayashi S, Oka M, Furuya R, Iwagami M, Tsutsumi D, Mochida Y, Maesato K, Ishioka K, Moriya H, Hidaka S.

J Cardiovasc Pharmacol Ther. 2013 Sep;18(5):439-46. doi: 10.1177/1074248413486355. Epub 2013 Apr 23.

PMID:
23615577
11.

Effects of switch from sevelamer hydrochloride to lanthanum carbonate on serum K and bone metabolic turnover.

Ota S, Hirose M, Izumiya Y, Ishida Y.

Ther Apher Dial. 2013 Apr;17 Suppl 1:49-53. doi: 10.1111/1744-9987.12044.

PMID:
23586513
12.

Lanthanum carbonate: a postmarketing observational study of efficacy and safety.

RombolĂ  G, Londrino F, Corbani V, Falqui V, Ardini M, Zattera T; Liguria and Toscana Lanthanum Experience (LITOLAE) Group..

J Nephrol. 2012 Jul-Aug;25(4):490-6. doi: 10.5301/jn.5000118.

PMID:
22476966
15.

Effect of calcium carbonate combined with calcitonin on hypercalcemia in hemodialysis patients.

Wei Y, Kong XL, Li WB, Wang ZS.

Ther Apher Dial. 2014 Dec;18(6):618-22. doi: 10.1111/1744-9987.12178. Epub 2014 Mar 27.

PMID:
24674384
16.

Control of parathyroid function in patients with a short history of hemodialysis.

Nishi H, Sato T, Kurihara T, Kurosawa T, Fukagawa M.

Ther Apher Dial. 2005 Feb;9(1):39-43.

PMID:
15828904
17.

Clinical experiences of bixalomer usage at our hospital.

Shima H, Makino R, Hata K, Ban A, Funao K, Sugita S, Furumitsu Y, Inoue K, Yoshimoto M, Okamura M.

Ther Apher Dial. 2014 Jun;18 Suppl 2:13-8. doi: 10.1111/1744-9987.12203.

PMID:
24975890
18.

The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease.

Freemont AJ, Hoyland JA, Denton J; Lanthanum Carbonate SPD405-303 Study Group..

Clin Nephrol. 2005 Dec;64(6):428-37.

PMID:
16370155
19.

Study of prolonged administration of lanthanum carbonate in dialysis patients.

Gotoh J, Kukita K, Tsuchihashi S, Hattori M, Iida J, Horie T, Onodera K, Furui H, Tamaki T, Meguro J, Yonekawa M, Kawamura A.

Ther Apher Dial. 2013 Apr;17 Suppl 1:9-14. doi: 10.1111/1744-9987.12043.

PMID:
23586507
20.

Salmon calcitonin in prevention of osteoporosis in maintenance dialysis patients.

Wang SX, Li H.

Chin Med J (Engl). 2008 Jul 20;121(14):1280-4.

PMID:
18713548

Supplemental Content

Support Center